Feb 4 (Reuters) - Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the ...

Time for Ozempic to walk the plank? Top dietitians in Australia this week are waving a red flag about an unforeseen impact of ...

A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.

Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide ...

Absolute risk for nonarteritic anterior ischemic optic neuropathy remained low, however ...

Ozempic® has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this GLP-1 (glucagon-like peptide 1 receptor agonist) ...

Ozempic and similar weight loss drugs offer major benefits for obesity and heart health, but side effects, muscle loss, and ...

Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...

Six pharmaceutical companies have applied to make a generic version of semaglutide, and competition will continue to heat up ...

Ozempic reunites Mac vs PC actors for new ads. The problem: diabetes drugs can't build social identity the way computers did ...